Clinical Scorecard: Evaluation of Treatment Efficacy, Follow-Up Outcomes, and Recurrence Trends in Pediatric Helicobacter pylori Infections

At a Glance

Key Highlights

• Overall eradication rate of 79.7% observed in treated children
• Amoxicillin-based regimen showed higher efficacy (84.0%) compared to metronidazole-based regimen (67.6%)
• Recurrence rate of 13.7% noted, particularly in children under 10 years
• Follow-up evaluations conducted at 6 and 12 months post-treatment
• Importance of long-term follow-up and antimicrobial resistance surveillance emphasized

Guideline-Based Recommendations

Diagnosis

• Diagnostic testing recommended for children with peptic ulcer disease or when endoscopic evaluation is indicated
• Empirical therapy often used in low-resource settings

Management

• Standard triple therapy with PPI and two antibiotics remains first-line treatment
• Customized therapy based on antibiotic susceptibility tests recommended where possible

Monitoring & Follow-up

• Follow-up assessments necessary to confirm treatment success and check for reinfection or recrudescence

Risks

• Rising antimicrobial resistance impacting treatment efficacy
• Higher likelihood of reinfection in children due to environmental and behavioral factors

Patient & Prescribing Data

Children aged 4–13 years with confirmed H. pylori infection

Amoxicillin-based therapy is more effective than metronidazole-based therapy

Clinical Best Practices

• Implement structured long-term follow-up for monitoring recurrence
• Conduct region-specific antimicrobial resistance surveillance
• Utilize non-invasive diagnostic methods like urea breath test for follow-up assessments

References

• European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines